ArticleRadiation oncology (London, England)2021
Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.
Article in Radiation oncology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Quality of life issues in patients with bone metastases: A systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Pooled it
- Integrating systemic therapy and metastasis-directed therapy in oligometastatic hormone-sensitive prostate cancer.Prostate cancer and prostatic diseases · 2026Review
- Stereotactic body radiation therapy for oligometastatic melanoma: a real-world study of the ESTRO/EORTC nomenclature.Radiation oncology (London, England) · 2026Article
- Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic/oligoprogressive castration resistant prostate cancer.Scientific reports · 2025Article
- Clinical outcomes and prognostic factors of stereotactic body radiation therapy in metastatic nasopharyngeal carcinoma.Therapeutic advances in medical oncology · 2025Article
- PSMA-PET/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancer.EJNMMI reports · 2024Article
- Abscisic acid signaling through LANCL2 and PPARγ induces activation of p38MAPK resulting in dormancy of prostate cancer metastatic cells.Oncology reports · 2024Article
- Article
- Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer.World journal of urology · 2023Article
- Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer.Pharmaceutics · 2023Review
- PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer.Diagnostics (Basel, Switzerland) · 2022Review
- Bone-only oligometastatic prostate cancer: can SABR improve outcomes? A single-center experience.Radiation oncology journal · 2022Article
- Radiotherapy in oligometastatic prostate cancer-a pattern of care survey among members of the German Society for Radiation Oncology (DEGRO).Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Article
- PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study.Clinical & experimental metastasis · 2022Article
- Review
- Imaging of Oligometastatic Disease.Cancers · 2022Review
- [Metachronous oligometastatic prostate cancer-the more the better or only local treatment?]Der Urologe. Ausg. A · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this work was to investigate the outcome of metastasis-directed radiotherapy (MDT) in prostate cancer patients with bone metastases following current ESTRO/EORTC subclassifications for oligometastatic disease.
methodsClinical data of 80 consecutive oligometastatic patients with 115 bone lesions receiving MDT between 2011 and 2019 were retrospectively evaluated. Hormone-sensitive (77.5%) and castrate-resistant (22.5%) patients were included. MDT was delivered with conventional fractionated or stereotactic body radiotherapy (SBRT) techniques. Kaplan-Meier method, log rank test, as well as Cox regression were used to calculate local control (LC) and biochemical and clinical progression-free survival (bPFS/cPFS).
resultsAt the time of MDT 31% of patients had de-novo synchronous oligometastatic disease, 46% had de-novo metachronous oligorecurrence after primary treatment and 23% had either de-novo oligoprogressive disease, repeat oligometastatic disease or induced oligometastatic disease. The median BED
conclusionsMDT is safe and offers high local control rates in bone oligometastases of prostate cancer. At 2 years after treatment, more than 2 out of 5 patients are progression-free. Trial registration Retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.